28 September 2012
Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells
Yinghui ChenAE, Yongbo ZhaoBD, Cuicui WangC, Xia XiaoB, Xiaoyong ZhouC, Guoxiong XuAEFDOI: 10.12659/MSM.883477
Med Sci Monit 2012; 18(10): BR383-388
Abstract
Background: Several studies have shown that multidrug transporters, such as P-glycoprotein (PGP), are involved in cell resistance to chemotherapy and refractory epilepsy. The p38 mitogen-activated protein kinase (MAPK) signaling pathway may increase PGP activity. However, p38-mediated drug resistance associated with PGP is unclear. Here, we investigated p38-mediated doxorubicin-induced drug resistance in human leukemia K562 cells.
Material/Methods: The expression of PGP was detected by RT-PCR, Western blot, and immunocytochemistry. Cell viability and half-inhibitory concentrations (IC50) were determined by CCK-8 assay. The intracellular concentration of drugs was measured by HPLC.
Results: A doxorubicin-induced PGP overexpression cell line, K562/Dox, was generated. The p38 inhibitor SB202190 significantly decreased MDR1 mRNA expression, as well as PGP, in K562/Dox cells. The IC50 of phenytoin sodium and doxorubicin in K562/Dox cells was significantly higher than that in wild-type K562 cells, indicating the drug resistance of K562/Dox cells. During the blocking of p38 activity in the presence of SB202190, cell number was significantly reduced after the phenytoin sodium and doxorubicin treatment, and the IC50 of phenytoin sodium and doxorubicin was decreased in K562/Dox cells. HPLC showed that the intracellular levels of phenytoin sodium and doxorubicin were significantly lower in K562/Dox cells than those in K562 cells. The decrease of the intracellular level of these drugs was significantly abolished in the presence of SB202190.
Conclusions: Our study demonstrated that p38 is, at least in part, involved in doxorubicin-induced drug resistance. The mechanistic study of MAPK-mediated PGP and the action of SB202190 need further investigation.
Keywords: Phenytoin - pharmacology, P-Glycoprotein - metabolism, Leukemia - pathology, K562 Cells, Drug Resistance, Neoplasm - drug effects, Doxorubicin - pharmacology, Dose-Response Relationship, Drug, Cell Survival - drug effects, Protein Kinase Inhibitors - pharmacology, p38 Mitogen-Activated Protein Kinases - metabolism
Editorial
04 June 2022 : Editorial
Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?DOI: 10.12659/MSM.937371
Med Sci Monit 2022; 28:e937371
In Press
23 Jun 2022 : Clinical Research
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...Med Sci Monit In Press; DOI: 10.12659/MSM.936706
22 Jun 2022 : Clinical Research
A Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...Med Sci Monit In Press; DOI: 10.12659/MSM.937316
21 Jun 2022 : Clinical Research
Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary PancreatitisMed Sci Monit In Press; DOI: 10.12659/MSM.937016
16 Jun 2022 : Clinical Research
Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic EraMed Sci Monit In Press; DOI: 10.12659/MSM.936497
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952